» Authors » Joseph F Mort

Joseph F Mort

Explore the profile of Joseph F Mort including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 20
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mort J, Brighton D, DiBenedetto S, Wells L, Clark S, Reid J, et al.
Eur J Haematol . 2024 Nov; 114(3):481-494. PMID: 39601208
Gemtuzumab ozogamicin (GO) is a CD33-targeting antibody-drug conjugate approved for the treatment of CD33-positive de novo and relapsed and refractory acute myeloid leukemia (AML). Subset analyses have demonstrated improved clinical...
2.
Mort J, Tran D, Dougherty S, Zielinski R, Williams M, Davidson K
Case Rep Hematol . 2023 Jun; 2023:9714457. PMID: 37388486
Immune thrombocytopenia (ITP) is an acquired thrombocytopenia resulting from immune-mediated platelet destruction via antiplatelet antibodies and T cells. Medical management of ITP includes corticosteroids and multiple other adjunct therapies, with...
3.
Mort J, Davis J, Mahoro G, Stotts M, Intagliata N, Northup P
Clin Gastroenterol Hepatol . 2020 Aug; 19(7):1436-1442. PMID: 32777555
Background & Aims: Studies of the effects of direct oral anticoagulants (DOACs) in patients with cirrhosis have been limited by their small sample size, inclusion of patients with well-compensated cirrhosis,...
4.
Mort M, Sen J, Morris A, DeGregory K, McLoughlin E, Mort J, et al.
J Oncol Pharm Pract . 2019 Sep; 26(3):680-687. PMID: 31500517
Background: Acute myeloid leukemia patients receive anthracycline-containing induction chemotherapy. Anthracyclines cause cardiotoxicity; however, there is a paucity of data reflecting the risk of cardiotoxicity in the acute myeloid leukemia population,...